JP2017504027A - 少量のサンプル容積から形成された血液構成成分沈降速度の迅速な測定 - Google Patents
少量のサンプル容積から形成された血液構成成分沈降速度の迅速な測定 Download PDFInfo
- Publication number
- JP2017504027A JP2017504027A JP2016547876A JP2016547876A JP2017504027A JP 2017504027 A JP2017504027 A JP 2017504027A JP 2016547876 A JP2016547876 A JP 2016547876A JP 2016547876 A JP2016547876 A JP 2016547876A JP 2017504027 A JP2017504027 A JP 2017504027A
- Authority
- JP
- Japan
- Prior art keywords
- centrifuge
- sample
- blood
- sedimentation
- hematocrit
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 238000004062 sedimentation Methods 0.000 title claims abstract description 179
- 239000012503 blood component Substances 0.000 title claims abstract description 85
- 238000005259 measurement Methods 0.000 title claims abstract description 77
- 238000000034 method Methods 0.000 claims abstract description 193
- 238000005534 hematocrit Methods 0.000 claims abstract description 145
- 210000004369 blood Anatomy 0.000 claims abstract description 123
- 239000008280 blood Substances 0.000 claims abstract description 123
- 238000005119 centrifugation Methods 0.000 claims description 75
- 238000007906 compression Methods 0.000 claims description 37
- 230000006835 compression Effects 0.000 claims description 36
- 239000000306 component Substances 0.000 claims description 35
- 238000001514 detection method Methods 0.000 claims description 20
- 238000000926 separation method Methods 0.000 claims description 18
- 238000005286 illumination Methods 0.000 claims description 11
- 239000000470 constituent Substances 0.000 claims description 10
- 230000000007 visual effect Effects 0.000 claims description 7
- 238000012544 monitoring process Methods 0.000 claims description 4
- 210000003743 erythrocyte Anatomy 0.000 abstract description 95
- 238000003384 imaging method Methods 0.000 abstract description 31
- 230000000694 effects Effects 0.000 abstract description 27
- 238000010191 image analysis Methods 0.000 abstract description 5
- 239000000523 sample Substances 0.000 description 181
- 210000002381 plasma Anatomy 0.000 description 59
- 238000012937 correction Methods 0.000 description 30
- 108010049003 Fibrinogen Proteins 0.000 description 24
- 102000008946 Fibrinogen Human genes 0.000 description 24
- 229940012952 fibrinogen Drugs 0.000 description 24
- 238000012360 testing method Methods 0.000 description 21
- 210000000265 leukocyte Anatomy 0.000 description 19
- 238000012545 processing Methods 0.000 description 16
- 230000008859 change Effects 0.000 description 14
- 230000006870 function Effects 0.000 description 13
- 210000004180 plasmocyte Anatomy 0.000 description 13
- 238000006243 chemical reaction Methods 0.000 description 10
- 230000009466 transformation Effects 0.000 description 10
- 102000001554 Hemoglobins Human genes 0.000 description 8
- 108010054147 Hemoglobins Proteins 0.000 description 8
- 238000003556 assay Methods 0.000 description 8
- 230000008569 process Effects 0.000 description 8
- 238000002835 absorbance Methods 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 230000000875 corresponding effect Effects 0.000 description 7
- 238000012986 modification Methods 0.000 description 7
- 230000004048 modification Effects 0.000 description 7
- 238000000691 measurement method Methods 0.000 description 6
- 210000001772 blood platelet Anatomy 0.000 description 5
- 238000004364 calculation method Methods 0.000 description 5
- 230000005499 meniscus Effects 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- JBRZTFJDHDCESZ-UHFFFAOYSA-N AsGa Chemical compound [As]#[Ga] JBRZTFJDHDCESZ-UHFFFAOYSA-N 0.000 description 4
- 102000004506 Blood Proteins Human genes 0.000 description 4
- 108010017384 Blood Proteins Proteins 0.000 description 4
- 108010074051 C-Reactive Protein Proteins 0.000 description 4
- 102100032752 C-reactive protein Human genes 0.000 description 4
- JMASRVWKEDWRBT-UHFFFAOYSA-N Gallium nitride Chemical compound [Ga]#N JMASRVWKEDWRBT-UHFFFAOYSA-N 0.000 description 4
- 230000002596 correlated effect Effects 0.000 description 4
- 238000011049 filling Methods 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 238000007620 mathematical function Methods 0.000 description 4
- 229910002601 GaN Inorganic materials 0.000 description 3
- 108060003951 Immunoglobulin Proteins 0.000 description 3
- 238000000149 argon plasma sintering Methods 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 102000018358 immunoglobulin Human genes 0.000 description 3
- 229940072221 immunoglobulins Drugs 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000007781 pre-processing Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 230000003068 static effect Effects 0.000 description 3
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 229910005540 GaP Inorganic materials 0.000 description 2
- 229910001218 Gallium arsenide Inorganic materials 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- 230000003044 adaptive effect Effects 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- FTWRSWRBSVXQPI-UHFFFAOYSA-N alumanylidynearsane;gallanylidynearsane Chemical compound [As]#[Al].[As]#[Ga] FTWRSWRBSVXQPI-UHFFFAOYSA-N 0.000 description 2
- MDPILPRLPQYEEN-UHFFFAOYSA-N aluminium arsenide Chemical compound [As]#[Al] MDPILPRLPQYEEN-UHFFFAOYSA-N 0.000 description 2
- RNQKDQAVIXDKAG-UHFFFAOYSA-N aluminum gallium Chemical compound [Al].[Ga] RNQKDQAVIXDKAG-UHFFFAOYSA-N 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 230000005484 gravity Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 229910052738 indium Inorganic materials 0.000 description 2
- APFVFJFRJDLVQX-UHFFFAOYSA-N indium atom Chemical compound [In] APFVFJFRJDLVQX-UHFFFAOYSA-N 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 238000000464 low-speed centrifugation Methods 0.000 description 2
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 2
- 229910052753 mercury Inorganic materials 0.000 description 2
- 229910001507 metal halide Inorganic materials 0.000 description 2
- 150000005309 metal halides Chemical class 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000000424 optical density measurement Methods 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 239000011574 phosphorus Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 230000001360 synchronised effect Effects 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 230000007704 transition Effects 0.000 description 2
- 229910052724 xenon Inorganic materials 0.000 description 2
- FHNFHKCVQCLJFQ-UHFFFAOYSA-N xenon atom Chemical compound [Xe] FHNFHKCVQCLJFQ-UHFFFAOYSA-N 0.000 description 2
- 238000012935 Averaging Methods 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical compound N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- GYHNNYVSQQEPJS-UHFFFAOYSA-N Gallium Chemical compound [Ga] GYHNNYVSQQEPJS-UHFFFAOYSA-N 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000030289 Lymphoproliferative disease Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000008601 Polycythemia Diseases 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 102000015395 alpha 1-Antitrypsin Human genes 0.000 description 1
- 108010050122 alpha 1-Antitrypsin Proteins 0.000 description 1
- 229940024142 alpha 1-antitrypsin Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000004581 coalescence Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 238000001446 dark-field microscopy Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- 239000012470 diluted sample Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 210000000624 ear auricle Anatomy 0.000 description 1
- 238000003708 edge detection Methods 0.000 description 1
- SFNALCNOMXIBKG-UHFFFAOYSA-N ethylene glycol monododecyl ether Chemical compound CCCCCCCCCCCCOCCO SFNALCNOMXIBKG-UHFFFAOYSA-N 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 210000000245 forearm Anatomy 0.000 description 1
- 229910052733 gallium Inorganic materials 0.000 description 1
- HZXMRANICFIONG-UHFFFAOYSA-N gallium phosphide Chemical compound [Ga]#P HZXMRANICFIONG-UHFFFAOYSA-N 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 208000009601 hereditary spherocytosis Diseases 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- UETZVSHORCDDTH-UHFFFAOYSA-N iron(2+);hexacyanide Chemical compound [Fe+2].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-] UETZVSHORCDDTH-UHFFFAOYSA-N 0.000 description 1
- 210000002414 leg Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229910052754 neon Inorganic materials 0.000 description 1
- GKAOGPIIYCISHV-UHFFFAOYSA-N neon atom Chemical compound [Ne] GKAOGPIIYCISHV-UHFFFAOYSA-N 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- NNFCIKHAZHQZJG-UHFFFAOYSA-N potassium cyanide Chemical compound [K+].N#[C-] NNFCIKHAZHQZJG-UHFFFAOYSA-N 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000007430 reference method Methods 0.000 description 1
- 230000033458 reproduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 208000007056 sickle cell anemia Diseases 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000012780 transparent material Substances 0.000 description 1
- BYGOPQKDHGXNCD-UHFFFAOYSA-N tripotassium;iron(3+);hexacyanide Chemical compound [K+].[K+].[K+].[Fe+3].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-] BYGOPQKDHGXNCD-UHFFFAOYSA-N 0.000 description 1
- WFKWXMTUELFFGS-UHFFFAOYSA-N tungsten Chemical compound [W] WFKWXMTUELFFGS-UHFFFAOYSA-N 0.000 description 1
- 229910052721 tungsten Inorganic materials 0.000 description 1
- 239000010937 tungsten Substances 0.000 description 1
- 238000000827 velocimetry Methods 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D21/00—Separation of suspended solid particles from liquids by sedimentation
- B01D21/30—Control equipment
- B01D21/32—Density control of clear liquid or sediment, e.g. optical control ; Control of physical properties
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D21/00—Separation of suspended solid particles from liquids by sedimentation
- B01D21/26—Separation of sediment aided by centrifugal force or centripetal force
- B01D21/262—Separation of sediment aided by centrifugal force or centripetal force by using a centrifuge
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D21/00—Separation of suspended solid particles from liquids by sedimentation
- B01D21/30—Control equipment
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
- G01N15/04—Investigating sedimentation of particle suspensions
- G01N15/05—Investigating sedimentation of particle suspensions in blood
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/483—Physical analysis of biological material
- G01N33/487—Physical analysis of biological material of liquid biological material
- G01N33/49—Blood
- G01N33/491—Blood by separating the blood components
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L3/00—Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
- B01L3/50—Containers for the purpose of retaining a material to be analysed, e.g. test tubes
- B01L3/502—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures
- B01L3/5021—Test tubes specially adapted for centrifugation purposes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
- G01N15/04—Investigating sedimentation of particle suspensions
- G01N15/05—Investigating sedimentation of particle suspensions in blood
- G01N2015/055—Investigating sedimentation of particle suspensions in blood for hematocrite determination
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Immunology (AREA)
- General Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- Food Science & Technology (AREA)
- Ecology (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Dispersion Chemistry (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Investigating Or Analysing Materials By Optical Means (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461930432P | 2014-01-22 | 2014-01-22 | |
| US61/930,432 | 2014-01-22 | ||
| PCT/US2015/012537 WO2015112768A1 (en) | 2014-01-22 | 2015-01-22 | Rapid measurement of formed blood component sedimentation rate from small sample volumes |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019236592A Division JP2020046442A (ja) | 2014-01-22 | 2019-12-26 | 少量のサンプル容積から形成された血液構成成分沈降速度の迅速な測定 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JP2017504027A true JP2017504027A (ja) | 2017-02-02 |
Family
ID=53681947
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016547876A Withdrawn JP2017504027A (ja) | 2014-01-22 | 2015-01-22 | 少量のサンプル容積から形成された血液構成成分沈降速度の迅速な測定 |
| JP2019236592A Withdrawn JP2020046442A (ja) | 2014-01-22 | 2019-12-26 | 少量のサンプル容積から形成された血液構成成分沈降速度の迅速な測定 |
| JP2022000958A Pending JP2022043307A (ja) | 2014-01-22 | 2022-01-06 | 少量のサンプル容積から形成された血液構成成分沈降速度の迅速な測定 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019236592A Withdrawn JP2020046442A (ja) | 2014-01-22 | 2019-12-26 | 少量のサンプル容積から形成された血液構成成分沈降速度の迅速な測定 |
| JP2022000958A Pending JP2022043307A (ja) | 2014-01-22 | 2022-01-06 | 少量のサンプル容積から形成された血液構成成分沈降速度の迅速な測定 |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP3097415A4 (es) |
| JP (3) | JP2017504027A (es) |
| CN (2) | CN106170696B (es) |
| CA (1) | CA2936828A1 (es) |
| MX (2) | MX2016009516A (es) |
| WO (1) | WO2015112768A1 (es) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2021502555A (ja) * | 2017-11-09 | 2021-01-28 | スピンチップ・ディグノスティックス・アーエス | 回転ディスク内に配置された回転カートリッジ内のサンプルに合焦する固定ビームの焦点を制御するための方法および装置 |
| JP2021522502A (ja) * | 2018-04-24 | 2021-08-30 | エンティア リミテッド | ヘモグロビン濃度を決定するための方法及び装置 |
| JP7413692B2 (ja) | 2019-09-25 | 2024-01-16 | 東ソー株式会社 | 細胞を含む試料の前処理方法 |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106446582A (zh) * | 2016-10-18 | 2017-02-22 | 江西博瑞彤芸科技有限公司 | 图像处理方法 |
| GB2555402B (en) * | 2016-10-24 | 2019-10-23 | Entia Ltd | A system and method for fluid analysis |
| WO2018132619A1 (en) * | 2017-01-11 | 2018-07-19 | Hemodus Medical, Llc | Method of estimating blood volume |
| JP7037324B2 (ja) * | 2017-01-27 | 2022-03-16 | 日本光電工業株式会社 | 炎症マーカー測定方法、炎症マーカー測定装置、炎症マーカー測定プログラム、および当該プログラムを記録した記録媒体 |
| JP7376587B2 (ja) * | 2018-07-09 | 2023-11-08 | サンドストーン ダイアグノスティックス インコーポレイテッド | 血漿分離及び保管用の装置及び方法 |
| CN111198262B (zh) * | 2018-11-19 | 2023-04-11 | 苏州迈瑞科技有限公司 | 一种用于尿液有形成分分析仪的检测装置及方法 |
| CN111537409B (zh) * | 2020-05-06 | 2022-10-14 | 南京邮电大学 | 一种高精度血沉温度补偿测量方法与装置 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH11506828A (ja) * | 1995-06-06 | 1999-06-15 | ブリガム・アンド・ウイメンズ・ホスピタル | 赤血球沈降速度及び赤血球容積率の決定 |
| US6204066B1 (en) * | 1999-06-25 | 2001-03-20 | Robert A. Levine | Rapid method for determining the erythrocyte sedimentation rate in a sample of anticoagulated whole blood |
| JP2009501324A (ja) * | 2005-07-13 | 2009-01-15 | アリファックス・インターナショナル・ソシエテ・アノニム | 赤血球沈降速度及び／又は赤血球凝集速度等、血液の濃度に関連する特性パラメータを分析する装置を較正する方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4197735A (en) * | 1978-11-06 | 1980-04-15 | Chase Instruments Corporation | Blood sedimentation rate test means |
| CA2230222A1 (en) * | 1997-03-10 | 1998-09-10 | Stephen C. Wardlaw | Method and assembly for rapid measurement of cell layers |
| GB9804560D0 (en) * | 1998-03-05 | 1998-04-29 | Zynocyte Ltd | Method of measuring erthrocyte sedimentation rate (esr),plasma viscosity and plasma fibrinogen of a blood sample |
| US6388740B1 (en) * | 1999-06-22 | 2002-05-14 | Robert A. Levine | Method and apparatus for timing intermittent illumination of a sample tube positioned on a centrifuge platen and for calibrating a sample tube imaging system |
| CN1256587C (zh) * | 2004-05-31 | 2006-05-17 | 苏州市第二人民医院 | 血液流变全血质控物及其制备方法 |
| US20110226045A1 (en) * | 2009-11-25 | 2011-09-22 | Mcquillan Adrian Charles | Liquid analysis system |
| US8475739B2 (en) * | 2011-09-25 | 2013-07-02 | Theranos, Inc. | Systems and methods for fluid handling |
-
2015
- 2015-01-22 WO PCT/US2015/012537 patent/WO2015112768A1/en active Application Filing
- 2015-01-22 JP JP2016547876A patent/JP2017504027A/ja not_active Withdrawn
- 2015-01-22 MX MX2016009516A patent/MX2016009516A/es unknown
- 2015-01-22 CN CN201580015419.7A patent/CN106170696B/zh active Active
- 2015-01-22 CN CN202010107295.8A patent/CN111562203A/zh active Pending
- 2015-01-22 CA CA2936828A patent/CA2936828A1/en not_active Abandoned
- 2015-01-22 EP EP15740716.4A patent/EP3097415A4/en not_active Withdrawn
-
2016
- 2016-07-21 MX MX2021013459A patent/MX2021013459A/es unknown
-
2019
- 2019-12-26 JP JP2019236592A patent/JP2020046442A/ja not_active Withdrawn
-
2022
- 2022-01-06 JP JP2022000958A patent/JP2022043307A/ja active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH11506828A (ja) * | 1995-06-06 | 1999-06-15 | ブリガム・アンド・ウイメンズ・ホスピタル | 赤血球沈降速度及び赤血球容積率の決定 |
| US6204066B1 (en) * | 1999-06-25 | 2001-03-20 | Robert A. Levine | Rapid method for determining the erythrocyte sedimentation rate in a sample of anticoagulated whole blood |
| JP2009501324A (ja) * | 2005-07-13 | 2009-01-15 | アリファックス・インターナショナル・ソシエテ・アノニム | 赤血球沈降速度及び／又は赤血球凝集速度等、血液の濃度に関連する特性パラメータを分析する装置を較正する方法 |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2021502555A (ja) * | 2017-11-09 | 2021-01-28 | スピンチップ・ディグノスティックス・アーエス | 回転ディスク内に配置された回転カートリッジ内のサンプルに合焦する固定ビームの焦点を制御するための方法および装置 |
| JP7195316B2 (ja) | 2017-11-09 | 2022-12-23 | スピンチップ・ディグノスティックス・アーエス | 回転ディスク内に配置された回転カートリッジ内のサンプルに合焦する固定ビームの焦点を制御するための方法および装置 |
| JP2021522502A (ja) * | 2018-04-24 | 2021-08-30 | エンティア リミテッド | ヘモグロビン濃度を決定するための方法及び装置 |
| JP7413692B2 (ja) | 2019-09-25 | 2024-01-16 | 東ソー株式会社 | 細胞を含む試料の前処理方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN106170696B (zh) | 2020-03-20 |
| JP2020046442A (ja) | 2020-03-26 |
| CA2936828A1 (en) | 2015-07-30 |
| JP2022043307A (ja) | 2022-03-15 |
| MX2021013459A (es) | 2021-12-10 |
| EP3097415A4 (en) | 2017-11-29 |
| WO2015112768A1 (en) | 2015-07-30 |
| CN111562203A (zh) | 2020-08-21 |
| EP3097415A1 (en) | 2016-11-30 |
| MX2016009516A (es) | 2016-10-26 |
| CN106170696A (zh) | 2016-11-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11320355B2 (en) | Rapid measurement of formed blood component sedimentation rate from small sample volumes | |
| JP2020046442A (ja) | 少量のサンプル容積から形成された血液構成成分沈降速度の迅速な測定 | |
| US10012638B2 (en) | Rapid measurement of formed blood component sedimentation rate from small sample volumes | |
| US9500639B2 (en) | Low-volume coagulation assay | |
| US20200264181A1 (en) | Measurement success/failure determination method and sample measurement device | |
| WO2022009104A2 (en) | Focusing a microscope using fluorescent images |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20180119 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20180122 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20181114 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20181228 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20190322 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20190527 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20190827 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20191226 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20200106 |
|
| A761 | Written withdrawal of application |
Free format text: JAPANESE INTERMEDIATE CODE: A761 Effective date: 20200108 |